More Than the Blues: The Role of Zuranolone in the Treatment of Postpartum Depression

Course overview

The birth of a child is a momentous occasion for the mother and family; however, for most mothers, it can be exhausting and accompanied by mood changes, apprehension, and unhappiness. When this experience is mild, it is referred to as the "baby blues." Beginning a few days after birth, baby blues typically last a couple of weeks. Sometimes, symptoms persist and worsen, developing into postpartum depression, a more severe condition. Untreated postpartum depression can adversely affect maternal and newborn well-being. Treatment of postpartum depression involves lifestyle changes, psychotherapy, and treatment with antidepressants. Zuranolone is the first FDA-approved oral medication indicated for postpartum depression. It has a rapid onset and may be an effective therapeutic option for mothers experiencing postpartum depression. This course discusses the benefits and risks of zuranolone so that the pharmacy team may provide effective patient counseling and contribute to a positive patient outcome.